Recently, the "Double Innovation Talent Plan" organized by the Jiangsu Provincial People's Government and the Provincial Talent Office was awarded a certificate of selection, and Dr. Wang Tong, Chief Scientific Officer of Shengshi Taike, was selected for the "2023 Jiangsu Province High level Innovation and Entrepreneurship Talent Introduction Plan". The Shengshi Taike R&D team led by Dr. Wang Tong is committed to the development of high-quality and differentiated small molecule innovative drugs, aiming to address major clinical pain points in the fields of blood sugar reduction, anti-tumor, and autoimmune diseases

Jiangsu Province's entrepreneurship and innovation talents focus on key industries that are prioritized for development in Jiangsu Province, introducing high-level entrepreneurial and innovative talents and teams, promoting the transformation and industrialization of a number of major scientific and technological achievements with independent intellectual property rights, incubating a group of high growth technology-based enterprises, driving a group of high-tech enterprises to enter the domestic first-class or international advanced ranks in independent innovation of core technologies and major products, and creating a group of rapidly developing and competitive high-tech product groups and enterprise groups.

CSO Dr. Wang Tong communicates with CEO Dr. Yu Qiang and the R&D team about the progress of research and development
Dr. Wang Tong, as the Chief Scientific Officer of Shengshi Taike, has over 20 years of experience in the full chain drug research and management of top pharmaceutical companies and research institutes in the United States. He is a strategic scientist who can break through key technologies, drive emerging disciplines, and promote the new drug industry. Since joining Shengshi Taike, I have been awarded the title of leading technology talent at all levels, bringing innovative thinking and advanced technological means to the company. I have integrated and formed a complete new drug development and industrialization platform, leading the company's R&D team to accelerate the development of new drug product pipelines. Many new drugs in the leading product pipeline have entered clinical and are about to be commercialized.
At present, the independently developed new generation of highly selective DPP-4 inhibitor, sengliptin (formerly known as sitagliptin), is about to be approved for market. Its clinical results show that compared with similar drugs already on the market, its "dosage" and "half work" therapeutic effect is expected to become the best hypoglycemic drug in its class; What is even more valuable is that its safety further solves the common adverse reactions in products already on the market. Among the anti-tumor drugs entering the clinical stage, CXCR4 antagonist CGT-1881 is used for hematopoietic stem cell mobilization and is the only original small molecule oral CXCR4 antagonist in China; The FGFR/VEGFR dual target inhibitor CGT-6321 is expected to become a potential first in class drug for the treatment of solid tumors; Based on the research and development project of CGT-6321, the company's executive team with Dr. Wang Tong as the core also won the Most Valuable Major Innovation Team Award among the Leading Talents in Gusu in 2022.

Shengshi Taike is a biotechnology company in the commercial stage, with its core product, Class 1 innovative drug sengliptin, about to be launched. The company was founded in Suzhou Industrial Park in 2010, and its core team has decades of experience in the entire lifecycle of international drugs, committed to the research and industrialization of high-quality and differentiated small molecule innovative drugs. The company has built a rich pipeline of innovative drugs covering hypoglycemic, anticancer, and autoimmune diseases through an integrated drug research and development technology platform and diversified business perspectives.